Given the success of FEM to identify causal epigenetic events in endometrial cancer and key pathways in ageing, we were impelled to explore the systematic application of FEM in the context of breast cancer and specifically to estrogen receptor (ER)-positive (ER+) breast cancer. Here, ESR1 is linked to endometrial cancer.